Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
58 hedge funds and large institutions have $57.1M invested in Zynerba Pharmaceuticals, Inc in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 16 closing their positions.
130% more call options, than puts
Call options by funds: $2.37M | Put options by funds: $1.03M
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
11% less funds holding
Funds holding: 65 → 58 (-7)
27% less capital invested
Capital invested by funds: $78.1M → $57.1M (-$20.9M)
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.59M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.49M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$611K |
| 4 |
Two Sigma Investments
New York
|
+$557K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$437K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
-$3.47M |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$1.45M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.3M |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$1.27M |
| 5 |
JP Morgan Chase
New York
|
-$945K |
ZYNE Hedge Fund Activity: Q3 2021 in Review
58 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q3 2021, worth a combined $57.1M — down 27% from $78.1M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ZYNE and 9 opened new positions — a net loss of 7 holders — while 18 trimmed existing stakes and 17 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.59M. The largest seller was IQ EQ Fund Management, cutting an estimated $3.47M.
- 58 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q3 2021, down from 65 in Q2 2021.
- Funds reported $57.1M of Zynerba Pharmaceuticals, Inc stock for Q3 2021, down 27% quarter-over-quarter.
- 9 funds opened new Zynerba Pharmaceuticals, Inc positions in Q3 2021 and 16 closed out, a net change of -7 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q3 2021 was Renaissance Technologies, an estimated $1.59M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q3 2021 was IQ EQ Fund Management, an estimated $3.47M sold.
Based on aggregated 13F filings for Q3 2021.